Predictive Factor Study of the Occurrence of Endometrial Cancer in Patients With Lynch Syndrome

Overview

Lynch Syndrome increases Endometrial Cancer Occurrence in women due to failure in MisMatch Repair System. Lifetime Cumulative risk of developing endometrial Cancer is approximatively 40% in women with Lynch Syndrome.

Endometrial cancer is the third women cancer in France. Many risk factors are known in general population. Lots of factors are related to over exposure to estrogen.

Data about influence of general risk factors in Women with Lynch Syndrome are poor. Recently, a cohort study appears to have shown a significant decrease in the risk of endometrial cancer with multiparity, the use of hormonal contraception and late menopause in Lynch women. The impact of weight and certain metabolic parameters on the occurrence of endometrial cancers remains poorly known to this day.

Full Title of Study: “Predictive Factor Study of the Occurrence of Endometrial Cancer in Patients With Lynch Syndrome: Study Conducted in the Hauts-de-France”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 2020

Interventions

  • Other: questionnaire assesment
    • Each patient will to answer questions about their medical history.

Arms, Groups and Cohorts

  • case group
    • Women with Lynch Syndrome and endometrial Cancer matched on age of endometrial cancer diagnosis
  • control group
    • Women with Lynch Syndrome, without Cancer at Lynch Syndrome Diagnostic matched on their age at Lynch Diagnostic

Clinical Trial Outcome Measures

Primary Measures

  • Correlation between endometrial cancer and predictif factors
    • Time Frame: Baseline
    • Endometrial cancer (yes/no) and explicative variable: Diabetes before endometrial cancer or Lynch syndrome diagnosis; Smoking ; Maximal Weight ; Age at menarche; Parity ; Age at first birth ; Contraceptive use.

Secondary Measures

  • Correlation between endometrial cancer and predictif factors in post menopausal woman
    • Time Frame: Baseline
    • Endometrial cancer (yes/no) and explicative variable: Menopause age; Hormonal menopause treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Lynch Syndrome Diagnosis at University Hospital
  • Alive at study time
  • Age over 30 at endometrial cancer or Lynch Syndrome Diagnosis

Case group :

  • No cancer before endometrial cancer diagnosis

Control group :

  • No endometrial cancer developped
  • Free cancer women at Lynch Syndrome diagnosis

Exclusion Criteria

  • Refusing to participate
  • Poor understanding of the French language
  • Other cancer diagnosed before endometrial cancer
  • Hysterectomy before lynch diagnosis for free cancer women

Gender Eligibility: Female

woman

Minimum Age: 30 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Lille
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Solveig MENU-HESPEL, MD, Principal Investigator, University Hospital, Lille
  • Overall Contact(s)
    • Solveig MENU-HESPEL, MD, 0320445962, solveig.menuhespel@chru-lille.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.